Merran Macpherson1, Bengt Hamrén2, Marjet J A M Braamskamp3,4, John J P Kastelein3,4, Torbjörn Lundström5, Paul D Martin6. 1. Wright Dose Ltd, Fifth Floor, Charter House, 2 Woodlands Road, Altrincham, Cheshire, UK. merran@wright-dose.com. 2. AstraZeneca, Mölndal, Sweden. Bengt.Hamren@astrazeneca.com. 3. Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. 4. Department of Pediatrics, Academic Medical Center, Amsterdam, The Netherlands. 5. AstraZeneca, Mölndal, Sweden. 6. AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK.
Abstract
PURPOSE: Data from two clinical studies (hyperCholesterolaemia in cHildren and Adolescents taking Rosuvastatin OpeN label [CHARON; NCT01078675] and Study 4522IL/0086) were used to describe rosuvastatin pharmacokinetics in patients with heterozygous familial hypercholesterolemia aged ≥6 to <18 years. METHODS: Rosuvastatin concentration-time data were analyzed via non-linear mixed-effects modeling (NONMEM), with clearance (CL/F) as the pre-defined key pharmacokinetic parameter of interest. In addition, descriptive comparisons between pediatric patients and adults (healthy and dyslipidemic) were performed. The dataset included 214 pediatric patients, with 2,029 rosuvastatin concentrations. RESULTS: A linear two-compartment model with first-order absorption and elimination processes adequately described the combined dataset. Weight and gender were significant covariates for CL/F, with moderate between-patient variability remaining (coefficient of variation (CV) 40 %): CL/F in female children was approximately 30 % lower than in male children, and there was a twofold mean difference in CL/F across the observed weight range. Age was not a significant covariate after accounting for weight and gender differences. However, weight and gender only reduced between-patient variability from 45 (without covariates) to 40 % and are considered unlikely to be clinically relevant. CONCLUSIONS: Rosuvastatin pharmacokinetics appeared generally predictable with respect to dose, and time (study duration) and the exposure (dose-normalized area under the plasma concentration-time curve at steady state (AUCss)) in children and adolescents appeared to be similar or lower than adult patients with dyslipidemia.
PURPOSE: Data from two clinical studies (hyperCholesterolaemia in cHildren and Adolescents taking Rosuvastatin OpeN label [CHARON; NCT01078675] and Study 4522IL/0086) were used to describe rosuvastatin pharmacokinetics in patients with heterozygous familial hypercholesterolemia aged ≥6 to <18 years. METHODS:Rosuvastatin concentration-time data were analyzed via non-linear mixed-effects modeling (NONMEM), with clearance (CL/F) as the pre-defined key pharmacokinetic parameter of interest. In addition, descriptive comparisons between pediatric patients and adults (healthy and dyslipidemic) were performed. The dataset included 214 pediatric patients, with 2,029 rosuvastatin concentrations. RESULTS: A linear two-compartment model with first-order absorption and elimination processes adequately described the combined dataset. Weight and gender were significant covariates for CL/F, with moderate between-patient variability remaining (coefficient of variation (CV) 40 %): CL/F in female children was approximately 30 % lower than in male children, and there was a twofold mean difference in CL/F across the observed weight range. Age was not a significant covariate after accounting for weight and gender differences. However, weight and gender only reduced between-patient variability from 45 (without covariates) to 40 % and are considered unlikely to be clinically relevant. CONCLUSIONS:Rosuvastatin pharmacokinetics appeared generally predictable with respect to dose, and time (study duration) and the exposure (dose-normalized area under the plasma concentration-time curve at steady state (AUCss)) in children and adolescents appeared to be similar or lower than adult patients with dyslipidemia.
Entities:
Keywords:
Children; Familial hypercholesterolemia; Pediatric; Population pharmacokinetics; Rosuvastatin
Authors: Tsang-Bin Tzeng; Dennis W Schneck; Bruce K Birmingham; Patrick D Mitchell; Harry Zhang; Paul D Martin; Li-Pin Kung Journal: Curr Med Res Opin Date: 2008-07-31 Impact factor: 2.580
Authors: Hans J Avis; Barbara A Hutten; Claude Gagné; Gisle Langslet; Brian W McCrindle; Albert Wiegman; Judith Hsia; John J P Kastelein; Evan A Stein Journal: J Am Coll Cardiol Date: 2010-03-16 Impact factor: 24.094
Authors: Brian J Anderson; Richard A van Lingen; Tom G Hansen; Yuan-Chi Lin; Nicholas H G Holford Journal: Anesthesiology Date: 2002-06 Impact factor: 7.892
Authors: Ch Van Kesteren; R A A Mathôt; E Raymond; J P Armand; Ch Dittrich; H Dumez; H Roché; J P Droz; C Punt; M Ravic; J Wanders; J H Beijnen; P Fumoleau; J H M Schellens Journal: J Clin Oncol Date: 2002-10-01 Impact factor: 44.544
Authors: Paul D Martin; Mike J Warwick; Aaron L Dane; Steve J Hill; Petrina B Giles; Paul J Phillips; Eva Lenz Journal: Clin Ther Date: 2003-11 Impact factor: 3.393